Regenxbio Stock Performance
| RGNX Stock | USD 9.59 0.41 4.47% |
The company holds a Beta of 2.31, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Regenxbio will likely underperform. At this point, Regenxbio has a negative expected return of -0.19%. Please make sure to check Regenxbio's standard deviation, potential upside, as well as the relationship between the Potential Upside and day median price , to decide if Regenxbio performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Regenxbio has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unfluctuating performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
Actual Historical Performance (%)
One Day Return 3.85 | Five Day Return 4.18 | Year To Date Return (45.69) | Ten Year Return (67.29) | All Time Return (67.29) |
1 | Insider Trading | 09/16/2024 |
2 | Acquisition by Pakola Steve of 32051 shares of Regenxbio subject to Rule 16b-3 | 09/26/2024 |
3 | Tagworks Pharmaceuticals Appoints Ken Mills as Chief Executive Officer | 10/01/2024 |
4 | Acquisition by Simpson Curran of 61050 shares of Regenxbio at 18.34 subject to Rule 16b-3 | 10/15/2024 |
5 | REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024 | 10/21/2024 |
6 | Regenxbio Inc Q3 2024 Everything You Need To Know Ahead Of Earnings | 11/05/2024 |
7 | Regenxbio GAAP EPS of -1.17 misses by 0.06, revenue of 24.2M misses by 0.2M | 11/06/2024 |
8 | Regenxbio Inc Q3 2024 Earnings Call Highlights Advancements in Gene Therapy and ... | 11/07/2024 |
9 | REGENXBIO Third Quarter 2024 Earnings EPS Misses Expectations | 11/08/2024 |
10 | Acquisition by Tasse Daniel of 4790 shares of Regenxbio subject to Rule 16b-3 | 11/13/2024 |
11 | Regenxbio up after announcement of pivotal program data | 11/14/2024 |
12 | Morgan Stanley bullish on Regenxbio stock, highlights gene therapy prospects | 11/15/2024 |
13 | Regenxbio price target lowered to 36 from 40 at H.C. Wainwright - TipRanks | 11/21/2024 |
| Begin Period Cash Flow | 99 M |
Regenxbio |
Regenxbio Relative Risk vs. Return Landscape
If you would invest 1,161 in Regenxbio on August 27, 2024 and sell it today you would lose (202.00) from holding Regenxbio or give up 17.4% of portfolio value over 90 days. Regenxbio is currently does not generate positive expected returns and assumes 4.6913% risk (volatility on return distribution) over the 90 days horizon. In different words, 41% of stocks are less volatile than Regenxbio, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Regenxbio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Regenxbio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Regenxbio, and traders can use it to determine the average amount a Regenxbio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0407
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | RGNX |
Estimated Market Risk
| 4.69 actual daily | 41 59% of assets are more volatile |
Expected Return
| -0.19 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Regenxbio is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Regenxbio by adding Regenxbio to a well-diversified portfolio.
Regenxbio Fundamentals Growth
Regenxbio Stock prices reflect investors' perceptions of the future prospects and financial health of Regenxbio, and Regenxbio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Regenxbio Stock performance.
| Return On Equity | -0.72 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | (2.83) % | ||||
| Operating Margin | (2.57) % | ||||
| Current Valuation | 303.74 M | ||||
| Shares Outstanding | 49.55 M | ||||
| Price To Earning | 12.80 X | ||||
| Price To Book | 1.58 X | ||||
| Price To Sales | 5.63 X | ||||
| Revenue | 90.24 M | ||||
| Gross Profit | (184.27 M) | ||||
| EBITDA | (239.46 M) | ||||
| Net Income | (263.49 M) | ||||
| Cash And Equivalents | 402.96 M | ||||
| Cash Per Share | 9.32 X | ||||
| Total Debt | 89.29 M | ||||
| Debt To Equity | 0.14 % | ||||
| Current Ratio | 4.06 X | ||||
| Book Value Per Share | 6.08 X | ||||
| Cash Flow From Operations | (218.41 M) | ||||
| Earnings Per Share | (5.01) X | ||||
| Market Capitalization | 475.14 M | ||||
| Total Asset | 573.97 M | ||||
| Retained Earnings | (705.05 M) | ||||
| Working Capital | 204.7 M | ||||
| Current Asset | 118.15 M | ||||
| Current Liabilities | 4.34 M | ||||
About Regenxbio Performance
Evaluating Regenxbio's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Regenxbio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Regenxbio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 106.97 | 101.62 | |
| Return On Tangible Assets | (0.46) | (0.48) | |
| Return On Capital Employed | (0.60) | (0.57) | |
| Return On Assets | (0.46) | (0.48) | |
| Return On Equity | (0.85) | (0.80) |
Things to note about Regenxbio performance evaluation
Checking the ongoing alerts about Regenxbio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Regenxbio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Regenxbio generated a negative expected return over the last 90 days | |
| Regenxbio has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 90.24 M. Net Loss for the year was (263.49 M) with loss before overhead, payroll, taxes, and interest of (184.27 M). | |
| Regenxbio currently holds about 402.96 M in cash with (218.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.32. | |
| Regenxbio has a poor financial position based on the latest SEC disclosures | |
| Over 92.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Regenxbio price target lowered to 36 from 40 at H.C. Wainwright - TipRanks |
- Analyzing Regenxbio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Regenxbio's stock is overvalued or undervalued compared to its peers.
- Examining Regenxbio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Regenxbio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Regenxbio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Regenxbio's stock. These opinions can provide insight into Regenxbio's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Regenxbio Stock Analysis
When running Regenxbio's price analysis, check to measure Regenxbio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regenxbio is operating at the current time. Most of Regenxbio's value examination focuses on studying past and present price action to predict the probability of Regenxbio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regenxbio's price. Additionally, you may evaluate how the addition of Regenxbio to your portfolios can decrease your overall portfolio volatility.